{
  "id": "5fe31307a43ad3127800003d",
  "type": "factoid",
  "question": "What percent of Rheumatoid Arthritis (RA) patients are not responding to anti-TNF therapy?",
  "ideal_answer": "These therapies are, however, expensive and 30% of patients fail to respond.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/16705046",
    "http://www.ncbi.nlm.nih.gov/pubmed/19211043",
    "http://www.ncbi.nlm.nih.gov/pubmed/18713756",
    "http://www.ncbi.nlm.nih.gov/pubmed/17354663",
    "http://www.ncbi.nlm.nih.gov/pubmed/27974105",
    "http://www.ncbi.nlm.nih.gov/pubmed/20444755",
    "http://www.ncbi.nlm.nih.gov/pubmed/17985409",
    "http://www.ncbi.nlm.nih.gov/pubmed/19389230",
    "http://www.ncbi.nlm.nih.gov/pubmed/25504080",
    "http://www.ncbi.nlm.nih.gov/pubmed/22133052",
    "http://www.ncbi.nlm.nih.gov/pubmed/25733803",
    "http://www.ncbi.nlm.nih.gov/pubmed/21431944"
  ],
  "snippets": [
    {
      "text": "Anti-tumour necrosis factor (TNF) agents have revolutionized the treatment of patients with rheumatoid arthritis (RA). These therapies are, however, expensive and 30% of patients fail to respond. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18713756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "By contrast, those patients who had failed to respond to 2 or more anti-TNF agents had a 72.5% lower probability of achieving a moderate to good EULAR response",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22133052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A 12-month EULAR non-response was observed in 153/821 (18.6%) associated with a higher baseline HAQ score (AOR 1.51, 95% CI 1.03-2.20, p: 0.033), prior treatment with >3 DMARDs (AOR 1.76, 95% CI 1.09-2.85; p: 0.021) and corticosteroid >5 mg/day (AOR 2.05, 95% CI 1.06-3.97; p: 0.034)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19211043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We found that only a minority of patients with long-standing RA treated with anti-TNF agents achieve a good clinical response or remission.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19211043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Agreement between responses was substantial at the overall/ACR20 level (about 95%, kappa = 0.7 or better) for all criteria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19389230",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After 6 months, 18% had a good EULAR response, of whom 9% were considered to be in remission and 50% had a moderate response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16705046",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-TNF treatments are effective and safe, reducing the activity of the disease, disability, and the need for corticosteroids. Patients who displayed good adherence prior to the anti-TNF treatment and were treated with etanercept or with increasing doses of infliximab had the best chance of displaying a response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17985409",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Anti-tumour necrosis factor (anti-TNF) therapy has proved to be highly successful in treating rheumatoid arthritis (RA), although 30-40% of patients have little or no r",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20444755",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although anti-TNF drugs have changed the clinical course of rheumatoid arthritis (RA), survival rates and resistance-to-therapy data confirm that about 30% of RA patients fail to respond. T",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25733803",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, 20-30% of patients do not respond sufficiently to a given anti-TNF drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17354663",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These therapies are, however, expensive and 30% of patients fail to respond.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18713756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "UNLABELLED: Approximately 30% of rheumatoid arthritis patients achieve inadequate response to anti-TN",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504080",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although TNF inhibitors have dramatically improved the outcome of patients with rheumatoid arthritis, 30-40% of patients do not respond well to them and treatment needs to be changed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431944",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "30%"
}